KR100951409B1 - 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 - Google Patents
수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 Download PDFInfo
- Publication number
- KR100951409B1 KR100951409B1 KR1020037009204A KR20037009204A KR100951409B1 KR 100951409 B1 KR100951409 B1 KR 100951409B1 KR 1020037009204 A KR1020037009204 A KR 1020037009204A KR 20037009204 A KR20037009204 A KR 20037009204A KR 100951409 B1 KR100951409 B1 KR 100951409B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- flt3l
- cells
- ifn
- sle
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
Abstract
Description
혈청 | MLR | IFN-α레벨 pg/ml | SLEDAI |
SLE 1 | 53% | ND | 20 |
SLE 2 | 58% | >500 | 8 |
SLE 3 | 27% | 192 | 12 |
SLE 4 | 28% | ND | 24 |
SLE 5 | 33% | >500 | 12 |
SLE 6 | 5% | <12.5 | 2 |
SLE 7 | 45% | 733 | 14 |
SLE 8 | 34% | 410 | 17 |
SLE 9 | 26% | >500 | 10 |
SLE 10 | 4% | <12.5 | 6 |
SLE 11 | 12.5% | 25 | 6 |
SLE 12 | 70% | >500 | 12 |
SLE 13 | 4% | <12.5 | 4 |
SLE 14 | 50% | ND | 4 |
SLE 15 | 10% | <12.5 | 6 |
SLE 16 | 16% | 78 | 6 |
SLE 17 | 30% | >500 | 8 |
SLE 18 | 60% | >500 | 17 |
SLE 19 | 7.5% | <12.5 | 14 |
SLE 20 | 4% | <12.5 | 2 |
AS(n=8) | 7% | <12.5 | |
연소성관절염 (n=2) | 3% | <12.5 | |
근피부염 (n=3)* | 4% | <12.5 | |
GM/IL4 | 100% |
Claims (81)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- (a) 타입Ⅰ인터페론의 활성을 감소시키며, 안티 IFN-α항체 또는 이들의 항원 결합 단편으로 이루어지는 적어도 하나의 인터페론 길항제, 및(b) Flt3L 리간드(Flt3L)의 활성을 감소시키며, 안티 Flt3L 항체 또는 이들의 항원 결합 단편으로 이루어지는 적어도 하나의 Flt3L 길항제를 포함하며, 후천성 면역 결핍증(AIDS), 강직성척추염(Ankylosing spondylitis), 관절염(arthritis), 재생불량성빈혈(aplastic anemia), 베체트병(be hcet's disease), 당뇨(diabetes), 이식편대숙주병(graft-versus-host disease), 그래브씨병(graves' disease), 용혈성 빈혈(hemolytic anemia), 저감마글로불린혈증(Hypogammaglobulinemia), 과 IgE 증후군(hyper IgE syndrome), 특발성 혈소판 감소성 자반증(idiopathic thrombocytopenicpurpura(ITP)), 다발성 경화증(mult iple sclerosis(MS)), 중증근무력증(Myasthenia gravis), 건선(psoriasis), 루푸스 및 이들의 조합으로 이루어진 그룹으로부터 선택되는 자가면역 질환을 치료하기 위한, 항원 제시를 할 수 있는 수지상 세포로의 단핵세포 분화를 억제하는 조성물.
- 삭제
- 제 28 항에 있어서,조성물이 담체를 더 포함하는 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 28 항 또는 제 30 항에 있어서,안티 IFN-α항체가 단일클론 항체, 키메릭(chimeric)항체, 항이디오타입 항체(anti-idiotypic) 항체, 인간화된 항체 또는 프리마티이즈(primatized)항체이고, 안티 Flt3L 항체가 단일클론 항체, 키메릭(chimeric)항체, 항이디오타입 항체(anti-idiotypic) 항체, 인간화된 항체 또는 프리마티이즈(primatized)항체인 조성물.
- 삭제
- 삭제
- 삭제
- 제 28 항에 있어서,조성물이 TNF를 더욱 포함하는 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 환자의 생물학적 샘플 내에서 Flt3L 및 IFN-α를 탐지하기에 효과적인 양으로 Flt3L 및 IFN-α와 특이적으로 결합하며, Flt3L과 결합하는 단일클론 항체 및 IFN-α과 결합하는 단일클론 항체로 이루어지는 조성물을 포함하며, 자가면역 질환 발현에 대한 환자의 위험을 측정하거나 환자 내의 자가면역 질환의 상태를 감시하기 위한 키트.
- 제 47 항에 있어서,생물학적 샘플이 혈액 샘플 또는 혈청 샘플인 키트.
- 삭제
- 제 47 항에 있어서,키트가 하나 또는 그 이상의 샘플들과 결합하는 조성물의 양을 측정하기 위한 하나 또는 그 이상의 시약들을 더 포함하는 키트.
- 제 47 항에 있어서,조성물이 식별가능한 마커로 식별화되는 키트.
- 제 51 항에 있어서,식별가능한 마커가 형광 마커, 방사성 마커, 효소 마커, 비색 마커, 화학발광 마커 및 이들의 조합으로 이루어진 그룹으로부터 선택되는 키트.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 28 항에 있어서,안티 IFN-α항체는 인간화된 항체이고 안티 Flt3L 항체는 인간화된 항체인 조성물.
- 제 47 항에 있어서,Flt3L과 결합하는 단일클론 항체는 인간화된 항체이고, IFN-α과 결합하는 단일클론 항체는 인간화된 항체인 조성물.
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26054101P | 2001-01-09 | 2001-01-09 | |
US60/260,541 | 2001-01-09 | ||
PCT/US2002/000343 WO2002067760A2 (en) | 2001-01-09 | 2002-01-08 | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030070100A KR20030070100A (ko) | 2003-08-27 |
KR100951409B1 true KR100951409B1 (ko) | 2010-04-07 |
Family
ID=22989575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037009204A KR100951409B1 (ko) | 2001-01-09 | 2002-01-08 | 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 |
Country Status (15)
Country | Link |
---|---|
US (3) | US7544357B2 (ko) |
EP (2) | EP2236156A3 (ko) |
JP (2) | JP4394350B2 (ko) |
KR (1) | KR100951409B1 (ko) |
CN (2) | CN101612402A (ko) |
AT (1) | ATE502648T1 (ko) |
AU (1) | AU2002246955B2 (ko) |
BR (1) | BR0206364A (ko) |
CA (1) | CA2433806C (ko) |
DE (1) | DE60239522D1 (ko) |
DK (1) | DK1351707T3 (ko) |
ES (1) | ES2363761T3 (ko) |
HK (1) | HK1061353A1 (ko) |
MX (1) | MXPA03006100A (ko) |
WO (1) | WO2002067760A2 (ko) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100951409B1 (ko) * | 2001-01-09 | 2010-04-07 | 베일러 리서치 인스티튜트 | 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 |
JP2007516984A (ja) * | 2003-12-24 | 2007-06-28 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 治療用物質およびそのための用途 |
ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
CN103251953A (zh) * | 2004-07-19 | 2013-08-21 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
EP2286835A1 (en) * | 2004-10-07 | 2011-02-23 | Universität Zürich Prorektorat Forschung | Type I interferon blocking agents for prevention and treatment of psoriasis |
US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
CN101155831B (zh) | 2005-02-10 | 2015-08-19 | 贝勒研究院 | 抗干扰素α单克隆抗体及其使用方法 |
CA2686861A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
NZ602007A (en) | 2008-01-18 | 2014-09-26 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
US20110059078A1 (en) | 2008-02-08 | 2011-03-10 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
AU2009245792B2 (en) * | 2008-05-07 | 2012-11-01 | Coimmune, Inc. | Humanized antibodies against human interferon-alpha |
WO2010055510A2 (en) | 2008-11-12 | 2010-05-20 | Yeda Research And Development Co. Ltd. | Diagnosis of multiple sclerosis |
CN101812119B (zh) * | 2009-02-25 | 2012-02-01 | 上海荣盛生物药业有限公司 | 与免疫抗体相结合的多肽及其应用 |
WO2012012694A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
SG10201505724SA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
SG191028A1 (en) | 2010-12-06 | 2013-07-31 | Thd Spa | Method for the diagnosis of a carcinoma and uses thereof |
US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
SG11201404570WA (en) * | 2012-02-10 | 2014-11-27 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
EP3385717A3 (en) | 2013-03-09 | 2018-10-24 | Harry Stylli | Methods of detecting prostate cancer |
KR101536697B1 (ko) * | 2013-11-29 | 2015-07-14 | 아주대학교산학협력단 | 베체트병 진단용 조성물 |
MA40636A (fr) | 2014-09-11 | 2015-09-11 | Colleen Kelly | Procédés pour détecter le cancer de la prostate |
CN111024936A (zh) | 2014-11-05 | 2020-04-17 | 纳迈达斯生物科技中心 | 用于增强成像的金属复合物 |
US10947295B2 (en) | 2017-08-22 | 2021-03-16 | Sanabio, Llc | Heterodimers of soluble interferon receptors and uses thereof |
US11512127B2 (en) * | 2018-02-14 | 2022-11-29 | Viela Bio, Inc. | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases |
WO2019204634A1 (en) * | 2018-04-20 | 2019-10-24 | Stc. Unm | Rap1-gtp, rac1-gtp and fms-like tyrosine kinase 3 ligand (flt3-l) as biomarkers for early detection of sepsis |
WO2019241158A1 (en) * | 2018-06-11 | 2019-12-19 | Univerity Of Washington | Compositions and methods for treating inflammatory diseases |
CN113238061B (zh) * | 2021-07-09 | 2021-10-01 | 中南大学湘雅医院 | 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用 |
WO2024083945A1 (en) * | 2022-10-20 | 2024-04-25 | Glaxosmithkline Intellectual Property (No.3) Limited | Antigen binding proteins |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0254647A2 (en) * | 1986-07-25 | 1988-01-27 | Mitsubishi Kasei Corporation | Medicines for treatment of autoimmune diseases |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
FR2490675B1 (fr) * | 1980-09-25 | 1985-11-15 | Genentech Inc | Production microbienne d'interferon de fibroplaste humain |
US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
DE3211263A1 (de) * | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US5582824A (en) * | 1981-10-19 | 1996-12-10 | Genentech, Inc. | Recombinant DES-CYS-TYR-CYS human immune interferon |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5096705A (en) * | 1981-10-19 | 1992-03-17 | Genentech, Inc. | Human immune interferon |
US5827694A (en) * | 1982-03-08 | 1998-10-27 | Genentech, Inc. | DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides |
US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
US4534906A (en) * | 1982-11-01 | 1985-08-13 | Genentech, Inc. | Removal of impurities from human leukocyte interferon preparations |
WO1984003106A1 (en) * | 1983-02-04 | 1984-08-16 | Wadley Inst Of Molecular Medic | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
US5196323A (en) * | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
US4851219A (en) * | 1986-11-18 | 1989-07-25 | Genentech, Inc. | Method for the treatment of chronic myelogenous leukemia |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
US5254678A (en) * | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
AU2844889A (en) | 1988-01-22 | 1989-07-27 | Collagen Corporation | Method for suppressing the growth of normal and cancer cells |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5889151A (en) * | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
DE69131426T2 (de) * | 1991-04-17 | 2000-01-27 | Medisup Int Nv | Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone |
US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
ES2092698T3 (es) * | 1991-08-30 | 1996-12-01 | Genentech Inc | Metodo terapeutico para el tratamiento de la diabetes mellitus dependiente de insulina (iddm). |
US5248499A (en) * | 1991-10-07 | 1993-09-28 | Genentech, Inc. | Control of microbial infections in transplant patients |
EP0563487A1 (en) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
US6630143B1 (en) * | 1993-05-24 | 2003-10-07 | Immunex Corporation | Antibodies against flt3 ligand |
NZ314644A (en) | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
AU7782894A (en) | 1993-09-17 | 1995-04-03 | Laboratoire Europeen De Biotechnologie S.A. | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5780027A (en) * | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
IL118096A0 (en) * | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6713609B1 (en) * | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
US5859183A (en) * | 1997-02-13 | 1999-01-12 | The Rockefeller University | Altered telomere repeat binding factor |
US20030018174A1 (en) * | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
EP0922758B1 (en) * | 1997-10-27 | 2009-04-15 | Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
ZA9811070B (en) * | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
EP1037995A1 (en) * | 1997-12-08 | 2000-09-27 | Genentech, Inc. | Human interferon-epsilon: a type 1 interferon |
US6291661B1 (en) * | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
AU784361C (en) | 1999-12-30 | 2007-03-15 | Imclone Systems Incorporated | Progenitor cell preservation factors and related methods and products |
GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
AU2001294577A1 (en) * | 2000-09-21 | 2002-04-02 | Schering Corporation | Methods for preparing interferon producing dentitric cells |
KR100951409B1 (ko) * | 2001-01-09 | 2010-04-07 | 베일러 리서치 인스티튜트 | 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
US6554512B2 (en) * | 2001-04-26 | 2003-04-29 | Zih Corp. | Printer for printing deformable flat supports and its loader |
WO2004094473A2 (en) | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
EP1711207B1 (en) * | 2003-12-10 | 2012-11-28 | Medarex, Inc. | Interferon alpha antibodies and their uses |
EP2286835A1 (en) | 2004-10-07 | 2011-02-23 | Universität Zürich Prorektorat Forschung | Type I interferon blocking agents for prevention and treatment of psoriasis |
-
2002
- 2002-01-08 KR KR1020037009204A patent/KR100951409B1/ko active IP Right Grant
- 2002-01-08 US US10/466,023 patent/US7544357B2/en not_active Expired - Lifetime
- 2002-01-08 WO PCT/US2002/000343 patent/WO2002067760A2/en active IP Right Grant
- 2002-01-08 AU AU2002246955A patent/AU2002246955B2/en not_active Expired
- 2002-01-08 EP EP10163628A patent/EP2236156A3/en not_active Withdrawn
- 2002-01-08 CA CA2433806A patent/CA2433806C/en not_active Expired - Lifetime
- 2002-01-08 JP JP2002567137A patent/JP4394350B2/ja not_active Expired - Fee Related
- 2002-01-08 DE DE60239522T patent/DE60239522D1/de not_active Expired - Lifetime
- 2002-01-08 MX MXPA03006100A patent/MXPA03006100A/es active IP Right Grant
- 2002-01-08 US US10/042,644 patent/US20020160974A1/en not_active Abandoned
- 2002-01-08 CN CN200910160480A patent/CN101612402A/zh active Pending
- 2002-01-08 AT AT02714705T patent/ATE502648T1/de active
- 2002-01-08 ES ES02714705T patent/ES2363761T3/es not_active Expired - Lifetime
- 2002-01-08 EP EP02714705A patent/EP1351707B9/en not_active Revoked
- 2002-01-08 CN CNB028035569A patent/CN100536919C/zh not_active Expired - Lifetime
- 2002-01-08 DK DK02714705.7T patent/DK1351707T3/da active
- 2002-01-08 BR BR0206364-6A patent/BR0206364A/pt not_active Application Discontinuation
-
2004
- 2004-04-14 HK HK04102607.7A patent/HK1061353A1/xx not_active IP Right Cessation
-
2009
- 2009-03-16 JP JP2009063336A patent/JP2009132736A/ja not_active Withdrawn
- 2009-05-04 US US12/435,267 patent/US20090263474A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0254647A2 (en) * | 1986-07-25 | 1988-01-27 | Mitsubishi Kasei Corporation | Medicines for treatment of autoimmune diseases |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
Also Published As
Publication number | Publication date |
---|---|
MXPA03006100A (es) | 2005-02-14 |
US20090263474A1 (en) | 2009-10-22 |
WO2002067760A3 (en) | 2003-03-13 |
EP1351707A4 (en) | 2004-12-15 |
EP1351707B1 (en) | 2011-03-23 |
JP2004519475A (ja) | 2004-07-02 |
US20020160974A1 (en) | 2002-10-31 |
ES2363761T3 (es) | 2011-08-16 |
CA2433806C (en) | 2011-03-15 |
AU2002246955B2 (en) | 2007-03-22 |
US20040067232A1 (en) | 2004-04-08 |
KR20030070100A (ko) | 2003-08-27 |
CN101612402A (zh) | 2009-12-30 |
DE60239522D1 (de) | 2011-05-05 |
JP2009132736A (ja) | 2009-06-18 |
EP2236156A2 (en) | 2010-10-06 |
HK1061353A1 (en) | 2004-09-17 |
DK1351707T3 (da) | 2011-07-11 |
EP1351707A2 (en) | 2003-10-15 |
WO2002067760A2 (en) | 2002-09-06 |
BR0206364A (pt) | 2005-08-16 |
JP4394350B2 (ja) | 2010-01-06 |
ATE502648T1 (de) | 2011-04-15 |
CN100536919C (zh) | 2009-09-09 |
US7544357B2 (en) | 2009-06-09 |
EP2236156A3 (en) | 2011-01-05 |
CN1529617A (zh) | 2004-09-15 |
EP1351707B9 (en) | 2012-01-25 |
CA2433806A1 (en) | 2002-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100951409B1 (ko) | 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트 | |
AU2002246955A1 (en) | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays | |
CA2558371C (en) | Methods of modulating immune responses by modulating tim-1 and tim-4 function | |
JP2008524242A (ja) | 自己免疫障害を治療する方法 | |
US20060039910A1 (en) | Methods and compositions for treating allergic inflammation | |
EP2950095B1 (en) | Cell-based assay and screening methods for modulators of p75NTR signaling | |
US20210275589A1 (en) | Co-receptor systems for treating infectious diseases | |
Seleznik et al. | The lymphotoxin β receptor is a potential therapeutic target in renal inflammation | |
WO2010085643A1 (en) | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders | |
JP2006512396A (ja) | 免疫寛容を誘導および維持する方法 | |
US20090208488A1 (en) | Regulation of dendritic cell functions by the DCAL-2 receptor | |
US20110275098A1 (en) | Method for Evaluating The Immunogenicity of Proteins | |
AU2007202840B2 (en) | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays | |
KR102237527B1 (ko) | 성숙 수지상 세포 검출용 바이오마커 및 이의 용도 | |
JP2006503899A (ja) | TGF−βの遮断により腫瘍再発を防ぐ方法 | |
US8246959B1 (en) | Dendritic cell-associated lectin-like molecules, compositions and methods of use | |
Ganguly | Activation and Functions of Plasmacytoid Dendritic Cells | |
Sinigaglia et al. | The Role of Stat4 in Species-Specific | |
KR101268562B1 (ko) | Tlt-6 단백질에 대한 항체 및 그 응용 | |
Chitnis et al. | Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis | |
Sutherland | BAFF regulation of peripheral T cell responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130312 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140312 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150310 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160311 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170320 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180312 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190315 Year of fee payment: 10 |